Neumora Therapeutics, Inc.

NMRA Nasdaq SEC CIK 1885522
Follow Neumora Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$34.4M +39.3% vs same quarter last year
EPS, diluted −$0.18 +48.6% vs same quarter last year
Operating cash flow −$33.4M +28.3% vs same quarter last year
Operating income −$33.4M +42.1% vs same quarter last year
Net income by quarter
$428.8M
−$68M
−$52.7M
−$56.8M
$414.4M
−$53.5M
−$43.1M
−$34.4M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing